Molecular therapies and precision medicine for hepatocellular carcinoma by Llovet i Bayer, Josep Maria et al.
Molecular therapies and precision medicine for hepatocellular carcinoma 1 






 and Richard S. Finn
3 
2 
1)Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, 3 
Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2)Liver Cancer Translational 4 
Lab, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, 5 
IDIBAPS, University of Barcelona, Barcelona, Spain. 3)Department of Medicine, Division of 6 
Hematology/ Oncology, Geffen School of Medicine, University of California, Los Angeles 7 
(UCLA), Los Angeles, CA, USA. 8 
Abstract | The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass an 9 
annual incidence of 1 million cases. Genomic studies have established the landscape of molecular 10 
alterations in HCC; however, the most common mutations are not actionable, and only ~25% of tumours 11 
harbour potentially targetable drivers. Despite the fact that surveillance programmes lead to early 12 
diagnosis in 40–50% of patients, at a point when potentially curative treatments are applicable, almost 13 
half of all patients with HCC ultimately receive systemic therapies. Sorafenib was the first systemic 14 
therapy approved for patients with advanced-stage HCC, after a landmark study revealed an 15 
improvement in median overall survival from 8 to 11 months. New drugs — lenvatinib in the frontline 16 
and regorafenib, cabozantinib, and ramucirumab in the second line — have also been demonstrated to 17 
improve clinical outcomes, although the median overall survival remains ~1 year; thus, therapeutic 18 
breakthroughs are still needed. Immune-checkpoint inhibitors are now being incorporated into the HCC 19 
treatment armamentarium and combinations of molecularly targeted therapies with immunotherapies 20 
are emerging as tools to boost the immune response. Research on biomarkers of a response or primary 21 
resistance to immunotherapies is also advancing. Herein, we summarize the molecular targets and 22 
therapies for the management of HCC and discuss the advancements expected in the near future, 23 
including biomarker-driven treatments and immunotherapies. 24 
Liver cancer is the second leading cause of cancerrelated death globally1 . Hepatocellular carcinoma 25 
(HCC) accounts for 90% of primary liver cancers and can be caused by chronic infection with hepatitis B 26 
virus (HBV) or hepatitis C virus (HCV), alcohol abuse, and metabolic syndrome related to diabetes and 27 
obesity2,3 . In developed countries, surveillance programmes lead to early HCC diagnosis in 40–50% of 28 
patients, at a stage amenable to potentially curative treatments2,4,5 . Patients with intermediate-stage 29 
HCC are treated with locoregional therapies, whereas those with advancedstage disease can benefit 30 
from systemic treatments2 . Overall, ~50% of patients receive systemic therapies at some point during 31 
the disease course2,4,5 . In a breakthrough study6 , the multi-target tyrosine kinase inhibitor (TKI) 32 
sorafenib, which has anti-angiogenic and anti-proliferative effects, extended the median overall survival 33 
of patients with advanced-stage HCC from 8 to 11 months and had a manageable toxicity profile. 34 
Sorafenib was the sole systemic therapy approved for the treatment of HCC between 2007 and 2016. In 35 
the past year or so, however, improvements in patient outcomes have been demonstrated in 36 
randomized phase III trials with lenvatinib7 in the frontline and regorafenib8 , cabozantinib9 , and 37 
ramucirumab10 in the second line after disease progression on sorafenib; regorafenib is currently FDA 38 
approved in the second-line setting. In addition, immunotherapy with nivolumab — a monoclonal 39 
antibody targeting the inhibitory immunecheckpoint molecule programmed cell death protein 1 (PD-1) 40 
— led to promising response rates and survival durations in a phase I–II study involving patients 41 
previously treated with sorafenib11 and has been granted accelerated approval by the FDA. By contrast, 42 
several kinase inhibitors (for example, sunitinib, brivanib, and erlotinib), doxorubicin, and 43 
radioembolization with yttrium 90 (90Y) -microspheres failed to improve overall survival in patients with 44 
unresectable HCC12.  45 
Indeed, HCC is a highly therapy resistant and thus difficult to treat cancer; although systemic therapies 46 
have clinical benefits, the improvements in patient outcomes have been modest and incremental. Thus, 47 
novel therapies for HCC remain an unmet medical need. In this regard, important insights into the 48 
biology of the disease have been obtained through genomic, transcriptomic, and epigenomic studies2,3 49 
. In this Review, we analyse the molecular targets and therapies for the management of HCC and 50 
highlight the advancements in biomarker-driven treatments and immunotherapies that are expected in 51 
the near future. 52 
The molecular landscape of HCC 53 
Molecular drivers 54 
 HCC development is a complex multistep process, with 70–80% of cases occurring in the context of 55 
established liver cirrhosis2,3 . The natural history of HCC in patients with cirrhosis progresses through a 56 
sequence of clinicopathological events starting with the appearance of pre-cancerous cirrhotic nodules 57 
(so-called dysplastic nodules), which can ultimately transform into HCC3 . Overall, one-third of patients 58 
with cirrhosis will develop HCC during their lifetime, with different rates per year observed according to 59 
aetiology2 . The median time between development of cirrhosis and the development of HCC is ~10 60 
years13. In the non-cirrhotic liver, HCC can arise principally on a background of HBV infection or 61 
nonalcoholic steatohepatitis and more rarely through the malignant transformation of hepatocellular 62 
adenoma, a monoclonal and typically benign lesion14. Malignant transformation from adenomas occurs 63 
in <10% of cases and has been associated with TERT and CTNNB1 mutations14. Mature hepatocytes 64 
have been identified as the cell of origin for most HCCs; however, a subset of ~20% of HCCs with 65 
progenitor cell markers, such as epithelial cell adhesion molecule (EPCAM) and cytokeratin 19 (CK19), 66 
can arise from either progenitor cells or dedifferentiated mature hepatocytes15.  67 
HCC results from the accumulation of somatic genomic and epigenomic alterations in the tissue of origin 68 
over time. In HCCs, an average of 40–60 somatic alterations are detected in protein-coding regions of 69 
the genome2,16. Most of these alterations occur in ‘passenger’ genes that are not directly implicated in 70 
neoplasia, but a few genomic alterations are considered to be ‘drivers’ involved in activating key 71 
signalling pathways for hepatocarcinogenesis. The identification of recurrently mutated genes and copy 72 
number alterations through integration of data from whole-exome sequencing (WES) studies and single-73 
nucleotide polymorphism (SNP) array analyses has enabled deciphering of these pivotal pathways, 74 
which include telomere maintenance, cell cycle control, WNT–β-catenin signalling, chromatin 75 
modification, receptor tyrosine kinase (RTK)–RAS–PI3K cascades, and oxidative stress16–21 (Table 1). 76 
Unfortunately, most of the clonal, ‘trunk’ mutations and prevalent drivers (TERT, CTNNB1, TP53, AXIN1, 77 
ARID1A, and ARID1B) detected in HCCs are not clinically actionable16 — at least at present. Indeed, 78 
reports of WES studies indicate that only ~25% of HCCs harbour alterations that are potentially 79 
targetable with existing drugs16. DNA methylation profiling also enabled the discovery of IGF2 80 
overexpression and CDKN2A silencing as epigenetic mechanisms of HCC tumorigenesis22. 81 
Molecular classifications 82 
Integrative molecular analyses involving genomic, transcriptomic, and/or epigenomic profiling of 83 
thousands of surgically resected tumours have provided the basis for the molecular classification of HCC 84 
subtypes21,23–26. These distinct molecular classes reflect different biological backgrounds with 85 
potential implications in patient prognostication and selection for therapies. Specifically, two major 86 
molecular subtypes of HCC, each encompassing ~50% of patients with this disease, have been proposed: 87 
a proliferation class and non-proliferation class3,27,28 (Fig. 1).  88 
As their designation suggests, HCCs of the proliferation class are characterized by activation of signalling 89 
pathways involved in cell proliferation and survival, such as the PI3K–AKT–mTOR, RAS–MAPK, and MET 90 
cascades21,23,24. Chromosomal instability seems to be a driving force in these tumours, with a 91 
particular enrichment of TP53 inactivation and FGF19 and/or CCND1 amplifications29. Our group and 92 
others3,27,28 have proposed that two subclasses exist within the proliferative class: a WNT–TGFβ group 93 
(also known as S1 tumours) characterized by non-canonical activation of WNT; and a progenitor cell 94 
group (also known as S2 tumours) characterized by overexpression of EPCAM, AFP, and IGF2, and a 95 
unique DNA hypermethylation signature30 (Fig. 1a). Overall, the proliferation class of HCC is associated 96 
with HBV-related aetiology and poor clinical outcomes.  97 
The non-proliferation class is more heterogeneous than the proliferative class and might consist of at 98 
least three HCC subclasses3,21 (Fig. 1). One clear subclass has been delineated and is characterized by 99 
activation of the canonical WNT signalling pathway, often owing to mutation of CTNNB1 (encoding β-100 
catenin)31, and is also associated with higher rates of TERT promoter mutations. From the clinical 101 
standpoint, non-proliferation class tumours are associated with alcohol-related and HCV-related 102 
aetiologies and better outcomes. These proposed molecular classes have been confirmed and further 103 
characterized in the comprehensive molecular analysis of 363 patients with HCC — the largest cohort 104 
published to date — reported by The Cancer Genome Atlas (TCGA) Research Network18. The integration 105 
of up to 5 other platforms — DNA copy number, DNA methylation, mRNA expression, microRNA 106 
(miRNA) expression, and reverse phase protein array (RPPA) assays — for 196 tumours yielded 3 107 
subtypes, including a poor prognosis iClust1 subtype with a gene expression profile that closely 108 
resembles that of the progenitor cell subclass tumours and a lower-grade iClust2 subtype that shares 109 
molecular and pathological characteristics (for example, CTNNB1 mutations and less frequent 110 
microvascular invasion) with the non-proliferation class. The third TCGA cluster, iClust3, generated a 111 
TP53 signature associated with chromosomal instability and poor prognosis. Beyond tumour cell-112 
intrinsic molecular aberrations, an altered tumour microenvironment (TME) is now recognized as a key 113 
enabling factor in the development of HCC32,33. In fact, HCC is a prototypical inflammationassociated 114 
cancer attributable to viral hepatitis or steatohepatitis (alcoholic or nonalcoholic). Multiple cell types 115 
interact with hepatocytes in the chronically inflamed liver, including lymphocytes, macrophages, stellate 116 
cells, and endothelial cells. In this regard, a novel molecular classification of HCC based upon immune 117 
status has been proposed34 (Fig. 1b). Through analyses of inflammatory gene-expression profiles, 118 
infiltrates, and regulatory molecules, 30% of HCCs could be classified into an ‘immune class’, with high 119 
levels of immune cell infiltration, expression of PD-1 and/or programmed cell death 1 ligand 1 (PD-L1), 120 
activation of IFNγ signalling, markers of cytolytic activity (such as granzyme B and perforin 1), and an 121 
absence of CTNNB1 mutations34. Within this class, two distinct ‘active immune’ and ‘exhausted 122 
immune’ subclasses, characterized by markers of an adaptive T cell response or exhausted immune 123 
response, respectively, have been identified34. The exhausted immune tumours express many genes 124 
regulated by TGFβ, which mediate immunosuppression and T cell exhaustion. An ‘immune excluded 125 
class’ accounting for ~25% of HCCs was characterized by T cell exclusion from the TME and CTNNB1 126 
mutations34. The immune exhausted class mostly overlaps with the proliferative WNT–TGFβ subclass, 127 
whereas the immune excluded class overlaps with the CTNNB1 mutated non-proliferative class. Our 128 
group is currently exploring whether the immune active class is associated with responsiveness to 129 
immune-checkpoint inhibitors and whether, conversely, the immune exhausted and/ or the immune 130 
excluded classes are associated with primary resistance to these agents.  131 
Clearly, further research is needed to translate the current knowledge of HCC biology into prognostic 132 
and predictive biomarkers in order to guide clinical decisionmaking and, ultimately, improve patient 133 
outcomes. In this regard, analysing the molecular landscape of tumour tissues obtained from patients 134 
with advancedstage HCC, predominantly through tumour-tissue and liquid biopsy procedures, is of 135 
crucial relevance because these are the patients who are actually treated with systemic therapies in 136 
clinical trials. Notably, the fact that systemic drugs with demonstrated survival benefits in patients with 137 
HCC (sorafenib, regorafenib, lenvatinib, cabozantinib, and ramucirumab) share an — at least partially — 138 
anti-angiogenic mechanism of action highlights the importance of this hallmark of cancer, which is 139 
mainly promoted by endothelial cells35. Indeed, angiogenic signalling is prominent in all subclasses of 140 
HCC36,37 . Understanding how the distinct angiogenic signalling pathways interact with the immune 141 
component of HCCs and how mechanisms of resistance to antiangiogenic agents arise could potentially 142 
reveal novel therapeutic strategies.  143 
Clinical management of HCC 144 
Several HCC staging systems have been proposed during the past four decades38–41; however, the 145 
Barcelona Clinic Liver Cancer (BCLC) staging classification is the most widely recognized clinical algorithm 146 
used for patient stratification and treatment allocation4,5,42. As mentioned previously, in developed 147 
countries, 40–50% of patients with HCC are diagnosed at early stages (BCLC stage 0–A), when potentially 148 
curative treatments (resection, liver transplantation, or local ablation) are possible4 . These treatments 149 
can result in median overall survival durations >60 months4 . Nevertheless, up to 70% of patients 150 
undergoing HCC resection or ablation present with disease recurrence within 5 years2 , and no adjuvant 151 
therapies tested to date are able to prevent this complication43. Patients with intermediate-stage 152 
disease (BCLC stage B) with preserved liver function (Child–Pugh class A without any ascites) can benefit 153 
from transarterial chemoembolization (TACE), as reported in two randomized studies comparing this 154 
approach with best supportive care44,45 and one meta-analysis46, with estimated median overall 155 
survival durations of 25–30 months. No combination of kinase inhibitors (such as sorafenib or 156 
brivanib)47–49 with TACE has been shown to provide additive improvements in patient outcomes. 157 
Nevertheless, most patients with HCC (>50%) will eventually receive systemic treatments: patients with 158 
disease progression after TACE or those who are diagnosed with advanced-stage HCC (BCLC stage C) can 159 
benefit from sorafenib6 . More recently, first-line lenvatinib7 and second-line regorafenib8 , 160 
cabozantinib9 , and ramucirumab10 have also been demonstrated to provide survival benefits for 161 
patients with advancedstage disease. In clinical trials, the median overall survival durations achieved 162 
with these therapies are around 1 year. Nivolumab is another new option in the secondline setting on 163 
the basis of the promising response rates and durations observed in the phase I–II trial of this agent11. 164 
Patients with end-stage disease (BCLC stage D) should be considered for nutritional and psychological 165 
support and appropriate management of pain. In 2018, international guidelines4 have been revised to 166 
provide updated recommendations on the treatment of HCC based on levels of evidence, encompassing 167 
all major treatments tested in this cancer (Fig. 2). 168 
Molecular targeted therapies 169 
First-line treatments 170 
Most patients with HCC are diagnosed at advanceddisease stages, at which the natural history of the 171 
disease carries a dismal prognosis. In this setting, conventional systemic chemotherapy lacks survival 172 
benefits. Phase III trials of doxorubicin alone, the PIAF regimen (cisplatin, IFNα2b, doxorubicin, and 173 
fluorouracil), and the FOLFOX4 regimen (fluorouracil, leucovorin (folinic acid), and oxaliplatin) all had 174 
negative results, in some instances with substantial toxicity50–52. Randomized studies also failed to 175 
prove any clinical effects of anti-oestrogen therapies or vitamin D derivatives53,54. 176 
Sorafenib. In 2007, results of the phase III SHARP trial6 demonstrated survival benefits with sorafenib 177 
versus placebo (median overall survival 10.7 months versus 7.9 months; HR 0.69, 95% CI 0.55–0.87; P < 178 
0.001), thus representing a breakthrough in the management of advanced-stage HCC. A similar 179 
magnitude of benefit was observed in another phase III study of sorafenib conducted in parallel in Asian 180 
patients, mostly with HBV-related HCC55. In these trials, treatment was generally associated with 181 
manageable adverse events (AEs), such as diarrhoea (grade 3 in 8–9%), hand–foot skin reactions (grade 182 
3 in 8–16%), fatigue (grade 3 in 3%), and hypertension (grade 3 in 2%). Intolerance to sorafenib 183 
(treatment discontinuation owing to AEs) typically occurs in 10–15% of patients6,55. The severity of 184 
toxicities — particularly hand–foot syndrome — has been associated with better survival outcomes in 185 
cohort studies56. A meta-analysis of the two phase III trials testing sorafenib revealed a consistent 186 
survival benefit across all clinical subgroups57. The greatest magnitude of the benefit was observed in 187 
patients with tumour confined to the liver, those who were HCV-positive, or those with a low 188 
neutrophil-to-lymphocyte ratio57. Sorafenib is indicated for patients with well-preserved liver function 189 
(Child–Pugh class A) and BCLC stage C disease or BCLC stage B disease that has progressed after 190 
locoregional therapy. Of note, the median overall survival of patients with BCLC stage B HCC treated 191 
with sorafenib is 15–20 months according to the findings of post-marketing studies58,59. Similarly, 192 
surveys conducted in >3,000 patients to evaluate the safety and tolerability of sorafenib in clinical 193 
practice reported median overall survival durations of 13.6 months for the Child–Pugh class A group and 194 
5.2 months for a Child–Pugh class B group60,61. From the mechanistic standpoint, the efficacy of 195 
sorafenib probably results from a balance between targeting cancer cells and cells of the TME: this 196 
agent can inhibit up to 40 kinases, including mainly angiogenic RTKs (including VEGF receptors (VEGFRs) 197 
and PDGF receptor-β (PDGFRβ)) and drivers of cell proliferation (such as RAF1, BRAF, and KIT)62. 198 
Unfortunately, at least partially owing to this pharmacological complexity, no predictive biomarkers of a 199 
response to sorafenib have been identified; however, the companion biomarker study conducted within 200 
the SHARP trial showed a nonsignificant trend towards a greater survival benefit of sorafenib in patients 201 
with tumours harbouring high levels of KIT and low plasma HGF concentrations63. The efficacy of 202 
sorafenib in the advanced-stage setting has led to testing of this drug at earlier clinical stages. In the 203 
phase II SPACE and phase III TACE 2 placebo-controlled trials involving patients with intermediate-stage 204 
HCC47,48, sorafenib plus TACE was safe, but the combination did not improve time to progression (TTP) 205 
in a clinically meaningful manner. Similarly, in the adjuvant setting after surgical resection or local 206 
ablation (phase III STORM trial)43, sorafenib did not improve recurrence-free survival (RFS) compared 207 
with that observed with placebo. A thorough molecular analysis of resected tumours from this trial 208 
enabled the design of a multi-gene signature that could be used to identify patients who benefited from 209 
adjuvant sorafenib treatment64; however, this biomarker test requires prospective validation. The 210 
successful SHARP trial6 provided a framework for trial design that has been implemented in subsequent 211 
phase III studies65. The main traits of this design are the selection of an adequate target population: 212 
patients with well-preserved liver function (Child–Pugh class A), to minimize the risk of liver failure and 213 
death as a result of cirrhosis, and patients with either advanced-stage (BCLC stage C) or intermediate-214 
stage (BCLC stage B) disease that has progressed following TACE, to provide clear results for this clinical 215 
stage. Moreover, overall survival was established as the most robust end point to assess efficacy in this 216 
population. Surrogate end points, such as TTP, have been associated with inconsistent results and are 217 
currently being revisited12. In this regard, use of the modified Response Evaluation Criteria in Solid 218 
Tumors (mRECIST), which are based on the concept of viable tumour, generally provides greater 219 
sensitivity in the assessment of response than the standard RECIST guidelines66; in phase III trials of 220 
sorafenib, objective response rates (ORRs) were 10–15% by mRECIST versus 2–6% by RECIST67. Several 221 
phase III trials have failed to demonstrate the superiority of a number of agents over sorafenib in the 222 
frontline setting (Fig.  3a). These therapies include brivanib (a selective VEGFR and FGF receptor (FGFR) 223 
TKI)68, sunitinib (a multi-target TKI with activity against VEGFRs, PDGFRs, and KIT)69, linifanib (a VEGFR 224 
and PDGFR TKI)70, and erlotinib (an EGFR inhibitor)71.  The reasons for the disappointing phase III trial 225 
results include overinterpretation of marginal antitumour efficacy in small phase II studies, considerable 226 
liver toxicity, flaws in trial design, and the lack of biomarker-based enrichment12. Moreover, the results 227 
of the phase III SARAH72 and SIRveNIB73 superiority trials of internal radiation with 90Y resin 228 
microspheres versus sorafenib in patients with advanced-stage HCC (including >30% with main portal 229 
vein thrombosis) did not fulfil the primary overall survival end points. In these studies72,73, median 230 
overall survival was 8.0–8.8 months in the 90Y-microsphere arms compared with 9.9–10.0 months in the 231 
sorafenib arms, resulting in nonsignificant detriments in survival with radioembolization (HR 1.12–1.15) 232 
(Fig. 3a). Per-protocol subgroup analyses did not reveal any survival advantages72,73. The authors of 233 
both trials highlighted the better response rates and quality of life (QOL) outcomes with 234 
radioembolization, thus suggesting this treatment as an alternative to sorafenib for selected patients. 235 
However, the indication of a therapy should be based upon the primary end point; therefore, the 236 
conclusion that the frontline treatment strategy can be decided on the basis of secondary end points is 237 
not sound. In addition, QOL outcomes typically have a negative correlation with time on therapy, which 238 
is clearly longer with sorafenib versus the one-time treatment with 90Y-microsphere radioembolization. 239 
Two additional phase III trials (STOP-HCC and SORAMIC) comparing combinations of 90Y glass 240 
microspheres plus sorafenib versus sorafenib alone have been initiated (NCT01556490 and 241 
NCT01126645). Preliminary results from the SORAMIC trial presented in abstract form in April 2018 242 
indicate that this combination does not improve survival74.  243 
Lenvatinib. Lenvatinib, an oral inhibitor of the VEGFRs, FGFR1–FGFR4, RET, KIT, and PDGFRα75, has 244 
been tested in phase II and phase III trials in patients with advanced-stage HCC7,76. In the phase III trial7 245 
, lenvatinib was found to be non-inferior to sorafenib in terms of overall survival (median 13.6 months 246 
versus 12.3 months; HR 0.92, 95% CI 0.79–1.06) (Fig. 3a). Importantly, the ORR in the lenvatinib group 247 
according to mRECIST was 24.1% when evaluated by investigators but reached 40.6% (versus 18% by 248 
RECIST) upon masked independent imaging review7 . Of note, patients with ≥50% liver occupation, 249 
obvious invasion of the bile duct, and/or invasion at the main portal vein were excluded from this 250 
study7 . In a subgroup analysis, patients with baseline serum α-fetoprotein (AFP) levels of >200 ng/ml 251 
had a greater benefit from lenvatinib than sorafenib (HR 0.78, 95% CI 0.63–0.98). The frequency of 252 
grade ≥3 treatment-related AEs was higher with lenvatinib than with sorafenib (57% versus 49%). The 253 
most common treatment-emergent AEs of any grade associated with lenvatinib were hypertension 254 
(42%), diarrhoea (39%), decreased appetite (34%), and decreased bodyweight (31%); 9% and 7% of 255 
patients treated with lenvatinib and sorafenib, respectively, discontinued treatment owing to 256 
treatment-related AEs. Fatal AEs related to lenvatinib treatment, including hepatic failure, cerebral 257 
haemorrhage, and respiratory failure, occurred in 2% of patients versus 1% of patients in the sorafenib 258 
arm.  259 
On the basis of these results, lenvatinib can be considered as an alternative first-line treatment option 260 
to sorafenib for patients with advanced-stage HCC (except those with main portal vein thrombosis or 261 
>50% liver involvement) or intermediate-stage disease after progression following TACE; FDA and 262 
European Medicines Agency (EMA) approvals are pending. Data from QOL studies suggest a similar 263 
overall profile for both drugs7 . No cost-effectiveness studies comparing both drugs have been reported 264 
to date. Similarly, no biomarkers predicting responses to either agent have been reported. 265 
Second-line therapies 266 
Since the approval of sorafenib in 2007, perhaps the largest unmet clinical need for patients with HCC 267 
has been in the second-line setting after disease progression on sorafenib. With therapies that improve 268 
overall survival without inducing high ORRs, such as sorafenib, identifying patients who are no longer 269 
benefiting from treatment is inherently challenging owing to difficulties in relating radiographic tumour 270 
measurements with clinical outcomes. Furthermore, in the pivotal phase III SHARP trial of sorafenib6 , 271 
patients were allowed to remain on treatment beyond radiological progression, ultimately adding 272 
additional layers of complexity. The decision to move novel therapies into phase III trials in the second-273 
line setting has generally been based on findings from single-arm studies with small cohorts of patients; 274 
ultimately, most of the randomized phase III trials did not meet their end points, including studies of 275 
agents targeting the mTOR77, VEGF78 and/or FGF79, or HGF– MET80 signalling pathways (Fig. 3b). Since 276 
2017, however, we have witnessed the reporting of positive results from three phase III trials in patients 277 
who had disease progression on, or were intolerant of, sorafenib8–10, as well as promising data from 278 
two phase II studies of different anti-PD-1 antibodies11,81. The results of these studies are now 279 
providing the clinicians with a number of secondline treatment options in the absence of comparative 280 
studies. Thus, treatment choices will need to be based on the sound data that are available and clinical 281 
judgement. Given the increasingly rapid pace of approvals, data on sequencing of the available agents is 282 
also lacking. As in other diseases, clinical factors that can influence secondline treatment choices include 283 
the first-line therapy used, the duration of response to that therapy, how treatment was tolerated, the 284 
clinical condition of the patient upon progression, and the expected efficacy and AEs of the available 285 
treatments.  286 
Regorafenib. Regorafenib has structural similarities to sorafenib, but the inhibitory profiles of these 287 
drugs differ slightly, with regorafenib having greater potency against the VEGFR kinases and a broader 288 
activity, for example, against angiopoietin 1 receptor (TIE2), KIT, and RET82. A small, single-arm phase II 289 
study of regorafenib provided some evidence of antitumour activity in the second-line setting83; 290 
however, the efficacy signals were not dissimilar from those obtained with other agents studied in this 291 
space. Nevertheless, the data led to the first positive phase III trial in patients with advanced-stage HCC 292 
for nearly a decade and the subsequent FDA approval of second-line regorafenib. The results of this 293 
global trial (RESORCE)8 demonstrated an improvement in the median overall survival of patients who 294 
had HCC progression on sorafenib from 7.8 months with placebo to 10.6 months with regorafenib (HR 295 
0.63, 95% CI 0.50–0.79; P < 0.0001) (Fig. 3b). Unlike other studies in this setting77–80, this trial required 296 
that patients not only have documented progression on sorafenib (according to RECIST) but also to have 297 
tolerated sorafenib for a minimum period of time (≥400mg daily for at least 20 of the 28 days before 298 
discontinuation)8 . Regorafenib also significantly improved secondary end points, including TTP (HR 299 
0.44, 95% CI 0.36–0.55; P< 0.0001). ORRs were higher with regorafenib versus placebo by both mRECIST 300 
and RECIST (10.6% versus 4.1% and 6.6% versus 2.6%, respectively). A subsequent evaluation of overall 301 
survival from the start of sorafenib treatment to death on study demonstrated a median duration of 26 302 
months for regorafenib-treated patients versus 19 months for those in the placebo arm84. Toxicities 303 
were manageable in this sorafenib-tolerant population and were similar to those observed with 304 
sorafenib, including hand–foot skin reaction, diarrhoea, and hypertension. 305 
Given the similarities between the two molecules, the exact mechanism of the benefit from regorafenib 306 
after progression on sorafenib is not clear. Besides continued suppression of VEGFR signalling and 307 
antiangiogenic effects, regorafenib has been hypothesized to directly inhibit pathways regulating 308 
tumour cell growth, proliferation, and metastasis and to modify the TME82. 309 
Cabozantinib. Cabozantinib is a small-molecule multitarget TKI with an inhibitory profile that is unique 310 
among the molecules evaluated in phase III studies in patients with HCC to date; in addition to activity 311 
against VEGFRs, this drug also potently inhibits MET and AXL85,86. Of note, the HGF receptor MET has 312 
been implicated in the pathogenesis of HCC and sorafenib resistance87. Cabozantinib was initially 313 
evaluated in both patients with untreated HCC and those with progression on, or intolerance of, 314 
sorafenib in a randomized phase II discontinuation study, resulting in an overall median PFS of 5.5 315 
months without substantial radiographical responses (2 of 41 patients had a partial response)86. 316 
CELESTIAL9 was a global, randomized, placebocontrolled, phase III trial of cabozantinib in patients who 317 
had HCC progression on prior sorafenib. Unlike in other studies, patients who had received up to two 318 
prior therapies for advanced-stage HCC were eligible for enrolment in CELESTIAL9 . This trial was 319 
stopped after a second interim analysis of data from the entire study population revealed a median 320 
overall survival of 10.2 months in the cabozantinib group versus 8.0 months in the placebo group (HR 321 
0.76, 95% CI 0.63–0.92; P=0.0049) (Fig. 3b). Approximately 72% of patients had received only prior 322 
sorafenib treatment, and in this subpopulation, median overall survival was 11.3 months with 323 
cabozantinib versus 7.2 months with placebo (HR 0.70, 95% CI 0.55–0.88)9 . Cabozantinib did not have a 324 
notable ORR (4% by RECIST), but did improve PFS and TTP9 . AEs with cabozantinib were as seen in 325 
earlier studies of this agent; the most frequent grade 3–4 AEs were hand– foot syndrome (in 17% of 326 
patients) and hypertension (in 16%)9 . Six grade 5 treatment-related AEs occurred with cabozantinib 327 
versus one with placebo9 . 328 
Ramucirumab. Unlike the small-molecule TKIs discussed so far, ramucirumab is an antagonistic anti-329 
VEGFR2 monoclonal antibody. On the basis of encouraging activity observed in a pilot study88, 330 
ramucirumab was compared with placebo in the phase III REACH trial involving patients with advanced-331 
stage HCC and prior sorafenib treatment78. The study was negative for its primary end point of overall 332 
survival in the intentionto-treat population, although a subgroup of patients with a baseline serum AFP 333 
levels ≥400ng/ml had a significant improvement in median overall survival from 4.2 months with 334 
placebo to 7.8 months with ramucirumab (HR 0.67, 95% CI 0.51–0.90; P=0.006). This observation paved 335 
the way for a second phase III trial of ramucirumab in the second-line setting (REACH-2; NCT02435433), 336 
this time incorporating biomarker-based enrichment for patients with baseline AFP concentrations 337 
≥400ng/ml. Results of this trial were reported in abstract form at the 2018 ASCO Annual Meeting10 and 338 
indicate a superior median overall survival duration of 8.5 months with ramucirumab versus 7.3 months 339 
with placebo (HR 0.71, 95% CI 0.53– 0.95; P=0.0199) (Fig. 3b) and a manageable safety profile (grade ≥3 340 
hypertension and hyponatraemia in 12.2% and 5.6%, respectively). Thus, ramucirumab becomes the 341 
first agent with a demonstrated clinical benefit for a biomarker-selected population of patients with 342 
HCC. AFP is a plasma glycoprotein that is produced in the liver, predominantly during early fetal 343 
development, but also in few tumour types, including HCC, hepatoblastoma, and non-seminomatous 344 
germ cell tumours of the ovary and testis89. Of note, ~40% of patients with advanced-stage HCC have 345 
serum levels of AFP ≥400ng/ml, and this feature is associated with poor prognosis63. Some studies have 346 
linked high AFP levels with higher microvessel densities and VEGFA expression in HCCs90. 347 
Immune-checkpoint inhibitors. The impact of treatments targeting immune checkpoints on oncology 348 
practice cannot be overstated: agents that target cytotoxic T lymphocyte protein 4 (CTLA-4), PD-1, or its 349 
ligand PD-L1 have revolutionized the management of many tumour types. A detailed description of the 350 
therapeutic mechanisms is beyond the scope of this Review, but in general, they involve blockade of 351 
negative feedback pathways of the immune system that mediate immunosuppression in the setting of 352 
malignancies91,92. For example, CTLA-4 is constitutively expressed in regulatory T cells but is also 353 
upregulated in cytotoxic T cells after T cell priming and is a dominant negative signalling molecule93. 354 
Monoclonal antibodies to CTLA-4, such as ipilimumab and tremelimumab, have been proven to block 355 
this negative feedback response and can lead to deep and durable responses in patients with cancer93. 356 
Similarly, PD-1 is a receptor expressed by T cells that provides negative regulatory signals predominantly 357 
during the effector phase of T cell responses. In the context of cancer pathogenesis, PD-1 on T cells can 358 
engage with its two known ligands, PD-L1 and PD-L2, in the TME to suppress anticancer immunity94. 359 
Monoclonal antibodies to either PD-1 (nivolumab and pembrolizumab) or PD-L1 (atezolizumab, 360 
avelumab, and durvalumab) are approved for the treatment of various malignancies95. HCC develops in 361 
an inflammatory milieu, and various studies have revealed a role for immune tolerance in the 362 
development of this cancer96, hinting at the potential of immune-checkpoint inhibition as an effective 363 
treatment strategy. Results of an initial phase II study of tremelimumab in a small cohort of patients 364 
with advanced-stage HCC (n = 20) demonstrated an ORR of 17.6% and a median TTP of 6.5 months97. 365 
Despite these signs of clinical efficacy, some safety concerns were raised, owing to transient but 366 
substantial increases in serum transaminase levels97. Notably, however, 43% of the patients enrolled 367 
had Child–Pugh class B liver disease97. More recently, nivolumab has been demonstrated to have 368 
single-agent activity in the much larger CheckMate 040 trial population, including patients with or 369 
without prior exposure to sorafenib11. In the phase I–II CheckMate 040 study11, a total of 262 eligible 370 
patients were treated with nivolumab, including 48 in the dose-escalation phase and another 214 in the 371 
dose-expansion cohort. Considering all patients included in the dose-expansion phase, the investigator-372 
assessed ORR was 20%, with 3 complete responses and 39 partial responses11. Most impressive, 373 
though, was the duration of response of 9.9 months among the patients who had an objective 374 
response11. Overall survival for patients in the secondline setting was 15.6 months98. Given the unmet 375 
needs in the second-line setting, the FDA granted accelerated approval to nivolumab for patients with 376 
advanced-stage HCC previously treated with sorafenib on the basis of the efficacy and safety data 377 
reported for a subpopulation comprising 154 sorafenib-treated patients included in CheckMate 040. In 378 
this subgroup, the ORR confirmed through blinded independent central review was 14.3% by RECIST 1.1 379 
and 18.2% by mRECIST and the median duration of response was 16.6 months99. The toxicity data from 380 
the second-line population of CheckMate 040 seems manageable, with the most frequent AEs being 381 
fatigue, musculoskeletal pain, pruritus and rash, and diarrhoea. Treatment-emergent grade 3–4 AEs 382 
included elevations in serum aspartate transaminase (AST), alanine transaminase (ALT), and bilirubin 383 
levels in 18%, 11%, and 7% of patients, respectively99. Importantly, no patient had on-treatment 384 
hepatic failure, and only 11% of patients had to discontinue treatment owing to AEs. As for other 385 
indications, patients with HCC need to be monitored closely during immune-checkpoint inhibition, as 386 
this class of agents can affect essentially any organ system. A confirmatory open-label, randomized 387 
phase III trial comparing sorafenib to nivolumab in the frontline setting is ongoing (CheckMate 459; 388 
NCT02576509); patient accrual is complete and the results are eagerly awaited. Pembrolizumab seems 389 
to have similar activity to nivolumab in patients with HCC. In KEYNOTE-224 (ref. 100), a single-arm study 390 
of pembrolizumab for second-line treatment after frontline sorafenib, the ORR in 104 patients was 391 
16.3%, including 1 complete response and 16 partial responses, and median overall survival was 12.9 392 
months. Toxicities included fatigue, AST elevations, diarrhoea, and itching; seven patients discontinued 393 
treatment owing to AEs81. Longerterm follow-up data from this study are awaited, as are the results of 394 
KEYNOTE-240, a randomized, placebo-controlled phase III trial of pembrolizumab101. Durvalumab, an 395 
anti-PD-L1 monoclonal antibody, has also been tested in a phase I–II trial that included a dose-expansion 396 
cohort of patients with HCC102. In this study102, durvalumab had an acceptable safety profile and 397 
demonstrated antitumour activity (ORR 10%). The challenges to the development of immunecheckpoint 398 
inhibitors in patients with HCC are similar to those faced with other targeted therapies, most 399 
importantly, relating to the identification of predictive biomarkers of response. In other malignancies, 400 
several biomarkers have been proposed, including PD-L1 and/or PD-1 expression by 401 
immunohistochemistry (IHC)103, a high tumour mutational burden104, and tumour T cell 402 
infiltration105. To date, data presented on nivolumab and pembrolizumab therapy for HCC have not 403 
shown any correlation between PD-L1 expression or underlying aetiology of cirrhosis and clinical 404 
benefit11,106. The FDA has approved pembrolizumab for the treatment of microsatellite instability-high 405 
or mismatch repair-deficient advanced-stage cancers. This indication is agnostic to tumour histology and 406 
therefore includes HCC; however, the incidence of these defects in HCC is estimated to be low (~3%)107. 407 
Combination strategies. The development of systemic therapies for HCC continues to benefit from 408 
knowledge gained in other tumour types. Combined CTLA-4 and PD-1 or PD-L1 blockade has been 409 
shown to improve survival outcomes, most notably in patients with melanoma108. In HCC, this 410 
approach is now being pursued in a phase III trial of durvalumab in combination with tremelimumab in 411 
the frontline setting (NCT03298451). The control arms of this trial include single-agent sorafenib and 412 
single-agent durvalumab. The trial is based on a phase I–II study evaluating the durvalumab–413 
tremelimumab combination109, which resulted in a confirmed ORR of 15% among 40 evaluable patients 414 
included in the phase I component. AEs were manageable and most commonly included fatigue, ALT 415 
and AST elevations, and pruritus; no unexpected toxicities were observed109. The combination of 416 
molecularly targeted therapies with immunotherapies is another area of active interest. Again 417 
borrowing from experiences in other diseases, impressive responses have been seen in patients with 418 
renal cell carcinoma (RCC) using the combination of lenvatinib and pembrolizumab (two drugs that have 419 
meaningful activity as single agents in this disease), resulting in a ‘breakthrough therapy’ designation 420 
from the FDA. In a study involving patients with non-HCC malignancies, those with RCC had an ORR to 421 
the lenvatinib and pembrolizumab combination of 63%; the median PFS and overall survival durations 422 
had not been reached at the time of presentation110. Toxicities were in keeping with those of the single 423 
agents, and no new safety signals were observed. This combination is now in development for the 424 
frontline treatment of HCC (NCT03006926), as is the combination of regorafenib and pembrolizumab 425 
(NCT03347292). These studies are building on the fact that these drugs have single-agent activity in 426 
patients with advanced-stage HCC, and as multi-target TKIs of VEGFRs and other kinases, lenvatinib and 427 
regorafenib have potential effects on the TME that might promote a response to immunotherapy36,37. 428 
Along those lines, monoclonal antibodies to VEGFA (bevacizumab) or VEGFR2 (ramucirumab) are being 429 
pursued in combination with PD-1 or PD-L1 inhibitors. Indeed, the combination of bevacizumab and 430 
atezolizumab is now being compared with sorafenib in a phase III study in the frontline setting 431 
(NCT03434379) and the FDA has granted this combination breakthrough designation on the basis of an 432 
ORR of 65% in 23 patients111 . Early phase studies evaluating the safety and efficacy of ramucirumab 433 
plus durvalumab in patients with HCC are underway (NCT02572687). 434 
Proof of concept for precision medicine  435 
As the above sections highlight, promising and robust clinical trial results have been presented in the 436 
past 2 years that are changing the treatment options for patients with advanced-stage HCC. All of the 437 
successful phase III studies yielded positive results without enriching for a biomarker-selected 438 
population, with the exception of REACH-2 (ref. 10). Despite the rapidly changing approach in other 439 
areas of oncology towards the development of molecularly targeted therapies in biomarkerselected 440 
populations112, this strategy is lacking in HCC. Nevertheless, attempts are being made at investigating 441 
this approach in patients with this disease (Fig. 4; Table 2). 442 
MET The MET RTK has nonmalignant roles in liver physiology but has been implicated in the 443 
development of HCC. For example, elevated expression of MET and its ligand HGF has been associated 444 
with poor prognosis and resistance to sorafenib87. Subgroup analyses of a phase II study testing the 445 
small-molecule MET inhibitor tivantinib in 107 patients previously treated with sorafenib revealed a 446 
correlation of high MET expression by IHC (≥2+ in ≥50% of tumour cells) with an unfavourable prognosis 447 
but improved survival with tivantinib versus placebo113. This concept was then tested in a prospective, 448 
randomized, phase III study in the second-line setting in patients with MET-high HCC. This study did not 449 
meet its primary end point of an improvement in overall survival with tivantinib versus placebo80 450 
(Fig. 3b). The placebo group of patients with MET-high HCC had a median overall survival of 9.1 451 
months80. This survival duration is the longest ever reported for patients with advanced-stage HCC in 452 
the context of a second-line phase III trial, raising the question of whether or not a high level of MET 453 
expression is a negative prognostic marker in this setting. Alternatively, the assay and the cut-off used 454 
for defining MET-driven HCC might not have been appropriate. In addition, tivantinib has been 455 
postulated to have a mechanism of action that is independent of MET inhibition114. Nevertheless, 456 
studies evaluating the activity of more-specific MET inhibitors as single agents and in combination with 457 
immunotherapy (for example, the small-molecule MET inhibitor capmatinib alone (NCT01737827) or in 458 
combination with the anti-PD-1 antibody spartalizumab (NCT02795429)) are ongoing in patients with 459 
HCC. The relative contribution of MET inhibition by cabozantinib to the proven efficacy of this agent in 460 
the second-line treatment of HCC remains to be determined.  461 
The FGF19– FGFR4 axis The FGF family consists of at least 5 RTKs and a large number of cognate ligands 462 
(at least 22) that have long been pursued as targets for anticancer treatments115. While FGFR2 463 
alterations are being pursued as therapeutic targets in several cancers116,117, in HCC, FGFR4 — the 464 
predominant FGFR expressed in the liver118 — has been identified as a potentially important target. 465 
FGF19 can bind to and activate FGFR4 and induce hepatocyte proliferation119. FGF19 amplification 466 
occurs in ~5–10% of HCC and has been shown to be an oncogenic driver implicated in sorafenib 467 
resistance120 and a potential predictive marker of response to FGFR kinase inhibitors121–123. Specific 468 
FGFR4 kinase inhibitors are moving through the clinical development pathway, including BLU-554 469 
(NCT02508467)124, H3B-6527 (NCT02834780)125, and FGF401 (NCT02325739). All these agents are 470 
being evaluated using a biomarker-based approach, primarily on the basis of IHC for FGF19, FGFR4, and, 471 
in some cases, β-klotho, a transmembrane protein that enhances FGF19–FGFR4 interaction and 472 
signalling. BLU-554 has progressed furthest in clinical development, and preliminary data in patients 473 
with advanced-stage HCC have shown a response rate of 16% to this agent in an FGFR4-driven group 474 
(defined by ≥1% tumour expression of FGF19 by IHC) versus 0% in the FGFR4-negative group126. 475 
Responses occurred regardless of FGF19-amplification status, and toxicities were generally low grade, 476 
including diarrhoea, nausea, vomiting, and elevated AST and/or ALT levels (transaminase elevations had 477 
an increased tendency to be of grade 3–4). Mature data are awaited while this drug class moves through 478 
development as single agents and potentially in combination with other agents, particularly immune-479 
checkpoint inhibitors (as in NCT02325739). 480 
Intracellular kinases Clearly, most efforts in HCC drug development have been focused on RTKs. 481 
However, several clinical studies have examined intracellular kinases as targets on the basis of 482 
preclinical and laboratory evidence. mTOR is a central kinase involved in signalling downstream of many 483 
RTKs implicated in HCC tumorigenesis127,128. Everolimus, an allosteric inhibitor of mTOR complex 1 484 
(mTORC1), has been evaluated in a phase III study as a second-line treatment of HCC77 but yielded 485 
negative results in an unselected patient population. A second-generation of mTOR pathway inhibitors 486 
(dual mTORC1 and mTORC2 inhibitors and mTOR–PI3K inhibitors) with a broader inhibitory action 487 
against PI3K–AKT signalling has been developed, and these agents are currently being investigated in 488 
early clinical trials (for example, NCT03059147)127,129. In contrast to everolimus, development of 489 
refametinib, a small-molecule MEK inhibitor, has been pursued in a biomarker-selected population. In a 490 
retrospective analysis of a single-arm phase II study evaluating refametinib plus sorafenib in patients 491 
with advanced-stage HCC, the best clinical responses were seen in patients with RAS mutations130. Two 492 
subsequent studies (NCT01915589 and NCT01915602) aimed to prospectively select patients on the 493 
basis of the presence of KRAS or NRAS mutations detected in serum circulating tumour DNA have been 494 
conducted using BEAMing technology; however, only 59 of 1,318 samples (4.4%) had detectable RAS 495 
mutations131 . A phase II combination trial enriched for RAS mutations testing refametinib plus 496 
sorafenib led to a median overall survival of 12.7 months in 16 patients131 . 497 
Future prospects  498 
Molecular characterizations have uncovered the most frequently mutated drivers (the TERT promoter, 499 
TP53, and CTNNB1), chromosomal aberrations (loss of 1q and 8p and high-level gains of 11q13 and 500 
6p21), and deregulated pathways (RAS–MAPK, WNT, mTOR, or IGF2 signalling, among others)2,3,16,20 501 
associated with HCC (Fig. 1; Table 1). Nonetheless, the advancements in the understanding of these 502 
molecular drivers have not yet been translated into biomarker-driven trials of precision medicine. In 503 
HCC, before the recently published REACH-2 trial10 , all effective drugs in phase III trials were multi-504 
kinase inhibitors with no known predictive biomarkers (Fig. 5). Similarly, positive data from studies of 505 
immune-checkpoint inhibitors have not been accompanied by companion diagnostic tools. Thus, an 506 
urgent need exists to implement genome-based HCC therapies and to understand predictors of 507 
response to immunotherapies or identify agents that are able to boost immune response in primary 508 
resistant tumours.  509 
Implementing driver-based therapies Molecular studies have already made great contributions to the 510 
understanding of HCC biology, but this knowledge has not been translated into clinical practice132. 511 
Strategic efforts are needed to foster precision medicine in this field. The co-development of predictive 512 
biomarkers together with novel targeted therapies is essential to overcome this issue133. In this regard, 513 
owing to the difficulties associated with the acquisition of biological samples of advanced-stage HCC, 514 
liquid biopsy — analyses of tumour cell-derived DNA and mRNA in cell-free plasma or circulating tumour 515 
cells — is envisioned as a useful tool to guide therapeutic decision-making in the near future134,135. A 516 
new drug development pathway has been established, consisting of positive proof-of-concept phase II 517 
trials — leading to accelerated approval — followed by phase III randomized studies versus the standard 518 
of care to support conventional approval. In addition, ‘monster’ phase I trials have emerged in the 519 
field136, consisting of studies including 1,000–2,000 patients, which include multiple amendments for 520 
establishing the final well-selected population that will define the target patient cohort. This clear 521 
strategy is based upon the following concepts of precision medicine. First, driver mutations lead to 522 
oncogenic addiction loops; therefore, molecular therapies blocking these oncogenic drivers achieve 523 
substantial responses (in general, ORRs of ~50%) and survival advantages. Second, clonal founder or 524 
trunk mutations can be assessed with single biopsy samples. Currently, >25 molecular therapies in 525 
oncology have been approved for use based upon a predictive biomarker of efficacy112. The percentage 526 
of patients with tumours harbouring a biomarker that guides therapies approved by regulatory agencies 527 
ranges from 0% (for example, in those with HCC or prostate or pancreatic cancer) to >40% (in those with 528 
melanoma and gastrointestinal stromal tumours)137. However, the percentage of patients with a 529 
genomic alteration with compelling clinical evidence of an association with a response is much higher 530 
(>40% in those with non-small-cell lung, endometrial, breast, or thyroid cancer, and approaching 20% in 531 
those with HCC), although the corresponding drug is not yet standard of care owing to a lack of strong 532 
evidence137. In HCC, the landscape of mutations and targetable drivers has been defined, and ~25% of 533 
them are considered potentially actionable16. Unfortunately, therefore, most trunk mutations and 534 
prevalent drivers in HCC138 (affecting the TERT promoter, CTNNB1, TP53, AXIN1, ARID1A, and ARID1B) 535 
are not directly actionable at present16. Thus, driver-based trials are scarce in this field. A few studies, 536 
for instance, assessing refametinib plus sorafenib in patients with RAS-mutated HCC131 or FGFR4 537 
inhibitors in patients with overexpression and/or amplification of FGF19 (refs124,125), have shown 538 
promise, whereas others failed (tivantinib in patients with METpositive HCC)80. According to the 539 
molecular pathogenesis and known pathways in HCC, drugs that block the effects of CTNNB1 mutations 540 
are expected to be relevant to precision medicine approaches. 541 
Immunotherapies — new opportunities Increased understanding of the mechanisms that govern 542 
tumour–host interactions has accelerated the development of novel immunotherapies for cancer. 543 
Indeed, several immune-checkpoint inhibitors obtained regulatory approval for the treatment of 544 
melanoma and lung, renal, and bladder cancers139. Despite this unprecedented success, responses 545 
typically occur in a minority of patients, ranging from 20% to 50% depending on the tumour type. In a 546 
small proportion of patients, immunotherapy can cause severe and potentially permanent autoimmune 547 
AEs140; therefore, the identification of candidate biomarkers to target patients who are most likely to 548 
benefit is becoming crucial. Unfortunately, only PD-L1 expression by IHC has been approved as a 549 
companion diagnostic (for lung cancer) or complementary test (for melanoma and bladder cancer) for 550 
anti-PD-1 treatments141. The FDA has also approved pembrolizumab for the treatment of solid tumours 551 
with microsatellite instability ((on the basis of immune-specific gene signatures), and overexpression of 552 
PTK2, an oncogenic pathway associated with poor T cell infiltration into tumours143. These data are 553 
consistent with findings in melanoma showing that activation of the β-catenin (CTNNB1) pathway is 554 
associated with T cell exclusion and resistance to immunotherapy144, suggesting that the immune 555 
exclusion class of HCC encompasses patients with ineffective or suboptimal responses to 556 
immunotherapies. Importantly, if the results of the ongoing phase III CheckMate 459 trial comparing 557 
nivolumab to sorafenib are positive, this immune-checkpoint inhibitor will become the standardof-care 558 
frontline therapy; thus, biomarker-driven identification of responders will not only improve therapeutic 559 
decision-making in the advanced-stage setting but also help to move immunotherapies to earlier clinical 560 
stages. Conversely, if the study fails to hit the primary end point, a clear understanding of the 561 
biomarkers for predicting a response or primary resistance to these agents will be essential for future 562 
efforts to establish immunotherapy as a treatment strategy for patients with HCC. 563 
Conclusions  564 
The global disease burden of HCC is increasing and might surpass an incidence of 1 million cases 565 
annually in the near future. In this regard, primary and secondary prevention policies along with 566 
improved implementation of surveillance programmes will be essential to reduce the morbidity and 567 
mortality associated with this disease. In fact, few patients with HCC (<10%) are cured. Thus, the 568 
majority of patients ultimately develop advanced-stage HCC, at which point only systemic therapies are 569 
effective in delaying the natural history of the disease (Fig. 5); however, the median overall survival of 570 
these patients remains ~1 year with the use of efficacious multi-kinase inhibitors. Immune-checkpoint 571 
inhibitors are now entering HCC clinical practice on the basis of promising early data. New phase III 572 
studies are expected to demonstrate even more promising outcomes with these agents in the frontline. 573 
Similarly, combinations of molecularly targeted therapies and immunotherapies are emerging as tools to 574 
boost responses of the immune system against HCCderived neoantigens. Hopefully, these strategies 575 
might raise the bar for systemic HCC therapy by extending median overall survival beyond 2 years, 576 
particularly if predictors of responsiveness are identified. In this scenario, systemic therapies might start 577 
competing with locoregional therapies, such as chemoembolization, for intermediate-stage HCC. 578 
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